Home Becton, Dickinson and Company

Becton, Dickinson and Company

BD Provides Update on Previously Disclosed Recall of BD Alaris System Hardware

Three of the situations described in this recall, which BD announced on June 30, 2020, have been designated as Class I recalls by the U.S. Food and Drug Administration (FDA), which means that there is a reasonable probability that the use of the product will cause serious adverse health consequences or death. One of the situations was designated as a Class II recall, which means the use of the product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

CME America Announces a Follow-Up on the Voluntary Recall of BodyGuard® Infusion System Administration Sets

As part of CME America's commitment to quality, following the previously announced recall (April 27, 2020) of the BodyGuard® Infusion Pump Systems, the company conducted additional flow-rate accuracy testing. This testing revealed that some infusion sets do not meet the ±5% delivery accuracy for the system or the ±13% accuracy identified in the earlier recall notification. Therefore, the use of the pump system potentially could cause over-infusion or under-infusion of therapy and patient harm.

BD, BioGX Announce FDA Emergency Use Authorization for New COVID-19 Diagnostic for Use in U.S.A.

The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for a new diagnostic test that will enable hospitals to screen for COVID-19 (coronavirus) on site and get results in under three hours.

BD Announces BD Kiestra™ ReadA is Now Available to U.S. Clinical Microbiology Laboratories

BD Kiestra™ ReadA provides closed-door incubation and high throughput imaging to streamline workflow, delivering high-quality images for digital interpretation by laboratory staff.

BD Completes Clinical Trial for BD Libertas™ Wearable Injector Completed

The award-winning injector* is a subcutaneous drug delivery system, currently in development, that is designed to require no patient assembly and deliver biologics with viscosities up to 50 cP in 2-5 mL and 5-10 mL configurations.

BD Intevia™ 1mL Two-step Disposable Autoinjector Launched

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch...

BD Provides Update on Voluntary Recalls of Alaris™ Pump Module Model 8100 and Certain Alaris™ Pump Infusion Sets

BD has already notified customers affected by these recalls. Both products were formerly marketed under the CareFusion brand, which BD acquired in March 2015. Both actions have been designated as a Class I recall by the U.S. Food and Drug Administration (FDA). Both recalls have been associated with medical device reporting (MDR) submissions, several of which are associated with serious injuries.

New Automated Flow Cytometry Sample Preparation Instrument with CE-IVD Certification Launched by BD

The new fully automated sample preparation instrument enables clinical laboratories to improve their efficiency by reducing errors and limiting the manual user interactions required to run assays on the BD FACSLyric™ clinical flow cytometer.